Mirla Avila and Susan Payrovi, MDs, explain MS progression, relapse vs. change, and subtle signs that matter even with a quiet MRI.

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Continued advancements in treatment and care are improving outcomes for people with MS. Multiple sclerosis (MS) develops when your immune system mistakenly attacks myelin, the protective coating that ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...